Solactis Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 3

Employees

  • Latest Deal Type
  • M&A

Solactis General Information

Description

Manufacturer of a bio-functional ingredient intended to improve colon and digestive functions. The company's product reduces transit time in the colon, improves digestive discomfort as well as reinforces immune defenses in the digestive system, thereby enabling users to get relief from gastric and other stomach pains and discomfort.

Contact Information

Website
www.solactis.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly Accelerator/Incubator backed
Corporate Office
  • Domaine de Vilvert - Bâtiment 325
  • 78352 Jouy-en-Josas
  • France
+33 01
Primary Industry
Biotechnology
Other Industries
Drug Delivery
Parent Company
The Greentech group
Vertical(s)
Manufacturing, HealthTech
Corporate Office
  • Domaine de Vilvert - Bâtiment 325
  • 78352 Jouy-en-Josas
  • France
+33 01

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Solactis Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 15-Apr-2021 Completed Generating Revenue
3. Secondary Transaction - Private 12-Oct-2015 Completed Generating Revenue
2. Accelerator/Incubator Completed Generating Revenue
1. Merger/Acquisition 25-Jul-2013 Completed Generating Revenue
To view Solactis’s complete valuation and funding history, request access »

Solactis Patents

  • 4

    Total Documents Applications and Grants

  • Total Patents Families

  • 3

    Granted

  • Pending

  • Expiring in next 12 mo

Solactis Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
ES-2636414-T3 Galactofructose due to its regulatory effect of intestinal transit Active 08-Feb-2011
EP-2672842-A1 Galactofructose for the regulatory effect thereof on intestinal transit Active 08-Feb-2011
EP-2672842-B1 Galactofructose for the regulatory effect thereof on intestinal transit Active 08-Feb-2011
EP-2584919-A1 Prebiotic effect of galactofructose Inactive 22-Jun-2010 A61K31/7016

Solactis Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Solactis Former Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
Agoranov Accelerator/Incubator Minority
Solvay Corporation Majority
To view Solactis’s complete investors history, request access »

Ready to get started?

Request a free trial

Solactis FAQs

  • When was Solactis founded?

    Solactis was founded in 2013.

  • Where is Solactis headquartered?

    Solactis is headquartered in Jouy-en-Josas, France.

  • What is the size of Solactis?

    Solactis has 3 total employees.

  • What industry is Solactis in?

    Solactis’s primary industry is Biotechnology.

  • Is Solactis a private or public company?

    Solactis is a Private company.

  • What is Solactis’s current revenue?

    The current revenue for Solactis is .

  • Who are Solactis’s investors?

    Agoranov and Solvay have invested in Solactis.

  • When was Solactis acquired?

    Solactis was acquired on 15-Apr-2021.

  • Who acquired Solactis?

    Solactis was acquired by Greentech (France).

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »